Department of Surgical Oncology;
Children's Hospital;
Zhejiang University School of Medicine;
Hangzhou 310052;
China;
Institute of Pharmacology and Toxicology;
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research;
College of Pharmaceutical Sciences;
Zhejiang University;
Hangzhou 310058;
China;
Cancer Center;
Zhejiang University;
Hangzhou 310058;
China;
Innovation Institute for Artificial Intelligence in Medicine;
Zhejiang University;
Hangzhou 310058;
China;
Pediatric Cancer Research Center;
National Clinical Research Center for Child Health;
Hangzhou 310052;
China;
Neuroblastoma; Differentiation therapy; High-risk; AKT; AKT inhibitor; Target therapy;